Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation
- PMID: 32425364
- PMCID: PMC7229910
- DOI: 10.1016/j.ejim.2020.05.018
Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation
Conflict of interest statement
Declaration of Competing Interest None.
Comment on
-
Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia.Eur J Intern Med. 2020 Jun;76:31-35. doi: 10.1016/j.ejim.2020.05.009. Epub 2020 May 13. Eur J Intern Med. 2020. PMID: 32405160 Free PMC article.
-
Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy.Eur J Intern Med. 2020 Jun;76:36-42. doi: 10.1016/j.ejim.2020.05.011. Epub 2020 May 21. Eur J Intern Med. 2020. PMID: 32448770 Free PMC article.
-
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.Eur J Intern Med. 2020 Jun;76:43-49. doi: 10.1016/j.ejim.2020.05.021. Epub 2020 May 22. Eur J Intern Med. 2020. PMID: 32482597 Free PMC article.
References
-
- Valade S., Mariotte E., Azoulay E. Coagulation disorders in hemophagocytic lymphohistiocytosis/macrophage activation syndrome. Crit Care Clin. 2020;36:415–426. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources